Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus (Q47398030)

15 January 2018

title

Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus (English)

1 reference

15 January 2018

author name string

R L Rubin

1

1 reference

15 January 2018

M Teodorescu

2

1 reference

15 January 2018

E H Beutner

3

1 reference

15 January 2018

R W Plunkett

4

1 reference

15 January 2018

publication date

1 January 2004

1 reference

15 January 2018

published in

Lupus

1 reference

15 January 2018

volume

13

1 reference

15 January 2018

issue

4

1 reference

15 January 2018

page(s)

249-256

1 reference

15 January 2018

Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Immunoglobulin classes and IgG subclasses of human antinuclear antibodies. A correlation of complement fixation and the nephritis of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

The Relation of Immunoglobulin Class, Pattern of Antinuclear Antibody, and Complement-Fixing Antibodies to DNA in Sera from Patients with Systemic Lupus Erythematosus*

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Immunologic factors and clinical activity in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Subclass restriction and polyclonality of the systemic lupus erythematosus marker antibody anti-Sm

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203304LU1007OA

10.1191/0961203304LU1007OA

21 January 2018

Identifiers

DOI

1 reference

15 January 2018

PubMed ID

15176661

1 reference

15 January 2018